Head-to-head evidence
Allo-RevCAR01-T vs Tagraxofusp
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
Allo-RevCAR01-T
Developed by AvenCell Europe GmbH
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT05949125 (registry estimate)
Tagraxofusp
Marketed by Stemline Therapeutics, Inc.
NCT02113982 · Phase 1/2 · completed
The study was non-randomized, open-label, single-arm, and had no comparator; although complete response is a clinical disease outcome, the main efficacy cohort included only 13 patients. Its reported response rate therefore provides limited controlled evidence for tagraxofusp, and no formal between-treatment primary endpoint comparison was applicable.
Next expected readout: April 2027 · NCT06498973 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Allo-RevCAR01-T's landscape · Tagraxofusp's landscape